The study authors conclude that a single ciltacaptagene-autoleucel (cilta-cel) infusion at the recommended phase 2 dose led to early and deep responses with manageable safety in patients with MM who had received 1–3 prior LOT. Updated efficacy and safety findings will inform the suitability of outpatient treatment in this and other cohorts of CARTITUDE-2 as well as the CARTITUDE-4 study.

The study authors conclude that Talquetamab, at the RP2D of weekly 405 μg/kg SC, demonstrated a high clinical response rate and was well-tolerated in patients with relapsed/refractory MM. Based on the pharmacokinetic data, other SC dosing strategies are also being explored. According to the authors, the promising efficacy and safety profile, and the convenience of SC dosing support monotherapy development and combination approaches with this novel agent.

The study authors conclude that Elranatamab demonstrated a manageable safety profile and wide therapeutic index. Doses ≥215μg/kg SC achieved ORR of 75% with CR/sCR rate of 30%. According to the authors, these results demonstrate the safety and efficacy of elranatamab in this relapsed/refractory population, confirm the feasibility and potential of BCMA- directed immunotherapy for malignant plasma cell disorders, and support ongoing development of elranatamab for patients with MM.

The study authors conclude that at the RP2D of weekly 1500 μg/kg SC, teclistamab was well-tolerated and demonstrated encouraging efficacy with durable, deepening responses, warranting further investigation as monotherapy and in combination with other agents.